Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06398639 · ClinicalTrials.gov registry record · NA
Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
A NA study of Prostate Cancer and Polygenic Risk Score, sponsored by Adam S. Kibel, MD.
- Recruiting
- Registry status
- NA
- Development phase
- 1,500
- Enrollment target
- 5
- Study locations
NCT06398639 is a NA study of Prostate Cancer and Polygenic Risk Score that is actively recruiting participants, run by Adam S. Kibel, MD. The registered enrollment target is 1,500 participants, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (148% higher). The trial reports 5 study locations across 3 states.
The verdict
NCT06398639, a NA study of Prostate Cancer and Polygenic Risk Score, is actively recruiting participants, sponsored by Adam S. Kibel, MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,500 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer. The main questions it aims to answer are: * If genetic data related to prostate cancer used with MRI can identify higher-grade, potentially fatal prostate cancer * What age a MRI is useful clinically for prostate cancer screening * If deep learning methods used with MRI when the genetic risk of the man is known can more accurately predict significant cancers Participants will: * Get a prostate specific antigen (PSA) blood test * Get an mpMRI * Get the results of their genetic data to determine if they are considered high-, intermediate-, or low-risk for prostate cancer based on the trials genetic testing * Follow-up for this trial based on the participants risk and findings from the PSA test and mpMRI
Conditions Studied
Interventions
- OTHER Polygenic Risk Score (PRS)
Study Locations (5)
Maryland
- National Cancer Institute - Bethesda
- Walter Reed National Military Medical Center - Bethesda
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
District of Columbia
- Howard University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2024-05-07 |
| Est. Completion | 2030-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06398639
The ClinicalTrials.gov registry entry for NCT06398639 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (148% higher). The listed sponsor is Adam S. Kibel, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Polygenic Risk Score (PRS) is the first listed.
NCT06398639 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Massachusetts, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06398639 about?
NCT06398639 is a clinical study titled "Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer". The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer. ...
What is the current status of trial NCT06398639?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,500 participants. The study started on 2024-05-07. Estimated completion is 2030-04-30.
What conditions does trial NCT06398639 study?
This clinical trial studies the following conditions: Prostate Cancer, Polygenic Risk Score.
What interventions are being tested in trial NCT06398639?
The interventions under investigation include: Polygenic Risk Score (PRS) (OTHER).
Who is sponsoring clinical trial NCT06398639?
This trial is sponsored by Adam S. Kibel, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06398639 being conducted?
This trial has 5 study locations across District of Columbia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.